Skip to content

Author

D. A. Ermokhina

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

EFFECTIVENESS AND SAFETY OF BARICITINIB IN CHILDREN WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

Baricitinib, a selective Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitor, was approved by the European Medicines Agency (EMA) in 2023 for the treatment of juvenile idiopathic arthritis (JIA) in children aged 2 years and older. Data on its use in routine clinical practice at Russian pediatric centers remain scar...

O. L. Lomakina, S. Valieva, E. Zholobova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.